GlassScriptPhysician profile
Aruna Potti
NPI 1649372749
$3,181.45
in general payments reported to CMS, 2019-2025
25 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $816 · 2021: $671 · 2022: $278 · 2023: $201 · 2024: $269 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $565.48 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $378.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $348.04 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $270.08 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $255.14 | 2019-2025 | |
| Amarin Pharma, INC. | $244.85 | 2019-2021 | |
| Abbvie INC. | $234.96 | 2021-2024 | |
| Amgen INC. | $227.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $149.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $78.90 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Arbor Pharmaceuticals, INC. | $64.36 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.54 | 2019-2025 | Xifaxan |
| Eisai INC. | $48.81 | 2021 | |
| Allergan, INC. | $47.08 | 2019-2020 | |
| Exact Sciences Corporation | $38.27 | 2024-2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26.67 | 2021 | |
| Medicure Pharma INC. | $23.68 | 2024 | Zypitamag |
| Astellas Pharma US INC | $16.93 | 2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $16.86 | 2019 | |
| Radius Health, INC. | $14.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2020 | |
| Abbott Laboratories | $14.45 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2022 | |
| Endo Pharmaceuticals INC. | $14.11 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Potti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.